Crispr Therapeutics Stock Hit on News of Rejection of Gene-Edited Cells

Crispr Therapeutics stock fell 13% after a scientists published a report detailing how human cells resist gene-editing by turning on defenses against cancer and killing the cells or preventing their reproduction.

Reported in the journal, “Nature Medicine,” the research raises concerns about the long-term effectiveness of gene therapy and the viability of crispr-Cas9 gene editing.

Two other companies saw their stocks decline on the news: Intellia Therapeutics and Editas Medicine.

“The reactions have been exaggerated,” said Jussi Taipale, a biochemist at the University of Cambridge and an author of one of two papers published Monday.

He added that far more research into the safety of Crispr is needed to draw any conclusions.